Abstract
The vitamin D receptor, a member of the nuclear receptor subgroup NR1I, is regulated by 1α,25(OH)2D3 to control calcium metabolism, cell proliferation and differentiation and immunomodulation. The therapeutic applications of vitamin D metabolites are wide. To develop efficient therapy, the elucidation of the structure-function relationships of VDR and its ligands are essential. In this review we will focus on the current structural understanding of the interactions of ligands in the ligand binding pocket of the VDR. These structures revealed the mutual adaptability of the ligands and the protein. In silico modeling has further revealed a possible new pocket in the VDR LBD responsible of the nongenomic action mediated by VDR. With the availability of all these structural information on VDR LBD, new ligands that are more selective, such as non-steroidal ligands, could be designed by taking into account the flexibility of some VDR regions. Tissue selectivity may also be achieved by developing ligands that specifically activate the non-genomic pathway.
Keywords: VDR, crystal structure, LBD, LBP, agonist, superagonist
Current Topics in Medicinal Chemistry
Title: Ligand Binding Domain of Vitamin D Receptors
Volume: 6 Issue: 12
Author(s): Natacha Rochel and Dino Moras
Affiliation:
Keywords: VDR, crystal structure, LBD, LBP, agonist, superagonist
Abstract: The vitamin D receptor, a member of the nuclear receptor subgroup NR1I, is regulated by 1α,25(OH)2D3 to control calcium metabolism, cell proliferation and differentiation and immunomodulation. The therapeutic applications of vitamin D metabolites are wide. To develop efficient therapy, the elucidation of the structure-function relationships of VDR and its ligands are essential. In this review we will focus on the current structural understanding of the interactions of ligands in the ligand binding pocket of the VDR. These structures revealed the mutual adaptability of the ligands and the protein. In silico modeling has further revealed a possible new pocket in the VDR LBD responsible of the nongenomic action mediated by VDR. With the availability of all these structural information on VDR LBD, new ligands that are more selective, such as non-steroidal ligands, could be designed by taking into account the flexibility of some VDR regions. Tissue selectivity may also be achieved by developing ligands that specifically activate the non-genomic pathway.
Export Options
About this article
Cite this article as:
Rochel Natacha and Moras Dino, Ligand Binding Domain of Vitamin D Receptors, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864926
DOI https://dx.doi.org/10.2174/156802606777864926 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Trifluoromethylated Derivatives on Prostaglandin E<sub>2</sub> and Thromboxane A<sub>2</sub> Production in Human Leukemic U937 Macrophages
Medicinal Chemistry Gene Therapy for Bone Regeneration
Current Pharmaceutical Design The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Iontophoretic Mediated Intraarticular Delivery of Deformable Liposomes of Diclofenac Sodium
Current Drug Delivery Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Human Galectin-1 and Its Inhibitors: Privileged Target for Cancer and HIV
Mini-Reviews in Medicinal Chemistry Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Advances in Noninvasive Pulmonary Gene Therapy
Current Drug Delivery Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging MicroRNAs as Cancer Biomarkers
MicroRNA